Grifols, S.A. (GRF.VI)

Are Investors Undervaluing Grifols (GRFS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

• 
  Are Investors Undervaluing CNO Financial Group (CNO) Right Now?

  Zacks
• 
  Are Investors Undervaluing Warner Bros. Discovery (WBD) Right Now?

  Zacks

Grifols (GRFS) Upgraded to Strong Buy: Here's Why

Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

• 
  What Makes Cadence (CDNS) a New Strong Buy Stock

  Zacks
• 
  What Makes First Business Financial Services (FBIZ) a New Strong Buy Stock

  Zacks

Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease

Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.